Author

William J. Sandborn 1

1 University of California San Diego,San Diego,United States

A CLUSTER-RANDOMISED CONTROLLED TRIAL OF AN ENHANCED TREATMENT ALGORITHM FOR THE MANAGEMENT OF CROHN’S DISEASE: REACT-2

Vipul Jairath, Reena Khanna, Leonard Guizzetti, Guangyong Zou, Joan Morris, Lisa Shackelton, Parambir Dulai, Humberto Aguilar, Oliver Brain, Matthew Brookes, Aminda De Silva, Michael S Epstein, Baroudi Fashir, John N. Gordon, William Harlan III, Ulf Helwig, Caroline Hwang, Pierre Laflamme, Rebecca Matro, Mark C. Mattar;;

A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ALPHA4BETA7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY

Scott Plevy, Bruce E. Sands, Julian Panés, Geert R. D'Haens, Vipul Jairath, Brian G. Feagan, Suneel Gupta, C. C. Hwang, Scott Lee, Alessandro Armuzzi, Walter Reinisch, Stefan Schreiber, William J. Sandborn

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A SELECTIVE, ORAL SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR, ETRASIMOD (APD334), IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE OASIS STUDY

William Sandborn, Laurent Peyrin-Biroulet, Luba Trokan, Jinkun Zhang, Tanja Kühbacher, Michael Chiorean, Scott D. Lee, Severine Vermeire, Bruce Yacyshyn, Snehal U. Naik, Preston Klassen, Julian Panés

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

Abivax - ABX464, a novel anti-inflammatory oral drug candidate based on a new mechanism of action to generate microRNA-124: From bench to bedside

William Sandborn, Jamal Tazi, Jean-Marc Steens

ABX464 (OBEFAZIMOD) IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: AN INTERIM 48-WEEK SAFETY AND EFFICACY ANALYSIS FROM AN ONGOING 96-WEEK OPEN-LABEL MAINTENANCE PHASE 2B STUDY

Severine Vermeire, Bruce E. Sands, Sophie Biguenet, Hartmut Ehrlich, Paul GINESTE, Josianne Nitcheu, William J. Sandborn

ADALILMUMAB SERUM CONCENTRATION AS A PREDICTOR FOR CLINICAL EFFICACY - ROC ANALYSES

Nael M. Mostafa, Anne M. Robinson, Shringi Sharma, William Sandborn, Subrata Ghosh, Stephen B Hanauer, Roopal B Thakkar, Walid Awni

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Geert R. D'Haens, Brian Feagan, William J. Sandborn, Remo Panaccione, Julian Panés, Tadakazu Hisamatsu, Marc Ferrante, Ezequiel Neimark, Peter Bossuyt, Silvio Danese, Alexandra Song, Xiaomei Liao, Tian Feng, Rachel Duan, Sofie Berg, Jean-Frédéric Colombel, Kori Wallace

Item 1 - 10 / 206
1
2 3 4 5 6 7
...
20 21